• Josip Begovac, Juraj Krznarić, Nikolina Bogdanić, Loris Močibob, and Šime Zekan.
• University Hospital for Infectious Diseases "Dr. Fran Mihaljević".
• Medicine (Baltimore). 2018 Dec 1; 97 (51): e13671.

RationaleData on anti-HCV therapy in patients on dialysis is still evolving. Sofosbuvir is mainly eliminated through the renal route and there is controversy about its use in these patients.Patient ConcernsWe describe a 53-year-old male patient with HCV genotype 3 and human immunodeficiency type 1 (HIV) infection on chronic dialysis. HIV infection was diagnosed in 1987 and since July 2007 the patient was compliant with his antiretroviral therapy (ART) and had an undetectable plasma HIV viral load on all follow-up measurements. The patient was known to have HCV infection since 1997 but has never been treated for chronic hepatitis C. Because of progressive renal impairment dialysis started in 2005.DiagnosisBefore anti-HCV treatment commenced the patient liver transient elastography (FibroScan) indicated F3 fibrosis (stiffness, 11.6 kPa) and his HCV RNA viral load was 320,798 IU/mL (Abbott RealTime HCV assay).InterventionFixed dose combination of sofosbuvir/velpatasvir (400 mg/100 mg) for 11 weeks.OutcomesTwelve weeks after treatment cessation HCV RNA was undetectable, hence the patient achieved a sustained virologic response. The drugs were well tolerated and the patient did not report any side effects.LessonsSofosbuvir/velpatasvir may be an option for HCV genotype 3 infection in patients coinfected with HIV on long-term dialysis.

22 keywords...

hide…